Cytokinetics will sell percentage of royalties on heart failure drug for $90 million
February 02, 2017 at 07:30 AM EST
The late-stage drug is being developed by Amgen and Cytokinetics.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|